KalVista Pharmaceuticals (KALV) Stock

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical firm dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. These inhibitors aim to address diseases with significant unmet medical needs. The company's core therapeutic strategy centers on its pipeline of small molecule plasma kallikrein inhibitors. These are specifically engineered to combat debilitating conditions such as hereditary angioedema (HAE) and diabetic macular edema (DME), with several formulated as oral treatments. Key products in their portfolio include: KVD001, a plasma kallikrein inhibitor that has successfully concluded a Phase II clinical trial for the treatment of DME. Sebetralstat, which is currently advancing into the Phase 3 KONFIDENT trial, poised to become an oral, on-demand therapeutic option for acute HAE attacks. KVD824, another oral candidate in development for the management of HAE. A Factor XIIa oral inhibitor program, which is in its preclinical stage, targeting a specific enzyme implicated in HAE. The company's main offices are located in Cambridge, Massachusetts.

KalVista Pharmaceuticals is led by CEO Benjamin L. Palleiko, employs 150 people, headquartered in US, publicly traded since 2015.

KalVista Pharmaceuticals (KALV) stock trades at $27.00 with a market capitalization of $1.44B. The stock is valued at a negative price-to-earnings (P/E) ratio of -8.28, reflecting a net loss over the last twelve months, price-to-sales of 12.30. Over the past 52 weeks the stock has ranged between $9.83 and $27.00, and currently trades at or near its 52-week high.

On profitability, KalVista Pharmaceuticals generates a return on equity (ROE) of 5466.67% (not meaningful, as shareholders' equity is negative), return on capital employed of 5733.33%, an operating margin of -232.43%, a net profit margin of -1.19%.

KalVista Pharmaceuticals by the numbers, 2017–2026

Between 2017 and 2026 KalVista Pharmaceuticals reported revenue of $2.0M rising to $74.0M, a change of +3600.0% across 10 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-164.0M.

Operating margin went from -1485.3% in 2017 to -233.4% in 2026, a gain of 1251.9 percentage points. The most recent net margin is -1.19%. On a trailing twelve-month basis to Mar '26, revenue is $116.0M and net profit $-137.0M.

Borrowings stand at $152.0M, cash from operations was $-82.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged 1022.1% over five years, and was 5466.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

KalVista Pharmaceuticals (KALV) — frequently asked questions